Current Neuro-Oncology
Volume
24 Number 21
15 November 2022
Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 21, 15 November
Teng
Y, Chen C, Zhang Y, Xu J.
The
feasibility of MRI texture analysis in distinguishing
glioblastoma, anaplastic astrocytoma and anaplastic
oligodendroglioma.
Transl
Cancer Res. 2022 Nov;11(11):4079-4088∟.
doi: 10.21037/tcr-22-1390∟.
PMID: 36523299∟.
Observational study. ˍ
Wang
E, Gutkin PM, Oh J, Pollom E, Soltys SG, Grant GA, Prolo LM, Chang
S, Li G, Fisher PG, Partap S, Campen CJ, Gibbs IC, Hiniker
SM.
Stereotactic
radiosurgery for recurrent pediatric brain tumors: clinical
outcomes and toxicity.
Neurosurg
Focus. 2022 Nov;53(5):E2∟.
doi: 10.3171/2022.8.FOCUS22361∟.
PMID: 36321285∟.
Observational study. ˍ
Chen
X, Momin A, Wanggou S, Wang X, Min HK, Dou W, Gong Z, Chan J, Dong
W, Fan JJ, Xiong Y, Talipova K, Zhao H, Chen YX, Veerasammy K,
Fekete A, Kumar SA, Liu H, Yang Q, Son JE, Dou Z, Hu M, Pardis P,
Juraschka K, Donovan LK, Zhang J, Ramaswamy V, Selvadurai HJ,
Dirks PB, Taylor MD, Wang LY, Hui CC, Abzalimov R, He Y, Sun Y, Li
X, Huang X.
Mechanosensitive
brain tumor cells construct blood-tumor barrier to mask
chemosensitivity.
Neuron.
2022 Nov 1, 2022:S0896-6273(22)00911-4∟.
doi: 10.1016/j.neuron.2022.10.007∟.
PMID: 36323321∟.
Laboratory investigation. ˍ
Liu
Y, Chen H, Li G, Zhang J, Yao K, Wu C, Li S, Qiu X.
Radiotherapy
delays malignant transformation and prolongs survival in patients
with IDH-mutant gliomas.
Cancer
Biol Med. 2022 Nov 1;19(10):1477–86∟.
doi: 10.20892/j.issn.2095-3941.2022.0472∟.
PMID: 36350001∟.
Observational study. ˍ
Fernandez-Gil
BI, Otamendi-Lopez A, Bechtle A, Vazquez-Ramos CA, Qosja N,
Suarez-Meade P, Sarabia-Estrada R, Jentoft ME, Guerrero-Cázares
H, Escames G, Schiapparelli P, Quiñones-Hinojosa
A.
Melatonin
Treatment Triggers Metabolic and Intracellular pH Imbalance in
Glioblastoma.
Cells.
2022 Nov 2;11(21):3467∟.
doi: 10.3390/cells11213467∟.
PMID: 36359862∟.
Laboratory investigation. ˍ
Mohammed S, Dinesan M, Ajayakumar
T.
Survival
and quality of life analysis in glioblastoma multiforme with
adjuvant chemoradiotherapy: a retrospective study.
Rep
Pract Oncol Radiother. 2022 Nov 2;27(6):1026-1036∟.
doi: 10.5603/RPOR.a2022.0113∟.
PMID: 36632307∟.
Observational study. ˍ
Smith
K, Nakaji P, Thomas T, Pinnaduwage D, Wallstrom G, Choi M,
Zabramski J, Chen C, Brachman D.
Safety
and patterns of survivorship in recurrent GBM following resection
and surgically targeted radiation therapy: Results from a
prospective trial.
Neuro
Oncol. 2022 Nov 2;24(S6):S4-S15∟.
doi: 10.1093/neuonc/noac133∟.
PMID: 36322102∟.
Interventional study. ˍ
Forster
MT, Hug M, Geissler M, Voss M, Weber K, Hoelter MC, Seifert V,
Czabanka M, Steinbach JP.
Outcome
and characteristics of patients with adult grade 4 diffuse gliomas
changing sites of treatment.
J
Cancer Res Clin Oncol. 2022 Nov 8∟.
doi: 10.1007/s00432-022-04439-7∟.
PMID: 36348019∟.
Observational study. ˍ
van der Meer PB, Koekkoek
JAF.
Valproic
acid in glioma: Will the anticancer issue ever be
solved?
Neurooncol
Pract. 2022 Nov 5, 2023;10(1):1-2∟.
doi: 10.1093/nop/npac091∟.
PMID: 36659971∟.
Editorial˰ ˍ
Montégut C, Guillamo JS,
Ducray F, Dehais C, Cohen-Jonathan Moyal E, Desenclos C, Petit A,
Seizeur R, Bekaert L, Gaultier C, Motuo Fotso MJ, Blonski M,
Frenel JS, Vauléon E, Langlois O, Noel G, Carpentier AF, Di
Stefano AL, Bronnimann C, Figarella-Branger D, Chinot O, Tabouret
E.
Characteristics,
Patterns of Care and Predictive Geriatric Factors in Elderly
Patients Treated for High-Grade IDH-Mutant
Gliomas: A French POLA Network Study.
Cancers
(Basel). 2022 Nov 9;14(22):5509∟.
doi: 10.3390/cancers14225509∟.
PMID: 36428602∟.
Observational study. ˍ
Schebesch
KM, Höhne J, Rosengarth K, Noeva E, Schmidt NO, Proescholdt
M.
Fluorescein-guided
resection of newly diagnosed high-grade glioma: Impact on extent
of resection and outcome.
Brain
Spine. 2022 Nov 9;2:101690∟.
doi: 10.1016/j.bas.2022.101690∟.
PMID: 36506293∟.
Observational study. ˍ
Ali
AS, Lombardo J, Niazi MZ, Miller RC, Alnahhas I, Martinez NL,
Andrews DW, Judy KD, Shi W.
Concurrent
chemoradiation and Tumor Treating Fields (TTFields, 200 kHz)
for patients with newly diagnosed glioblastoma: patterns of
progression in a single institution pilot study.
J
Neurooncol. 2022 Nov 10∟.
doi: 10.1007/s11060-022-04146-w∟.
PMID: 36355259∟.
Interventional study˰ ˍ
*
Girardi
F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard
JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N,
Coleman MP, Allemani C; CONCORD Working Group.
Global
survival trends for brain tumors, by histology: analysis of
individual records for 556,237 adults diagnosed in 59 countries
during 2000-2014 (CONCORD-3).
Neuro
Oncol. 2022 Nov 10, 2022:noac217∟.
doi: 10.1093/neuonc/noac217∟.
PMID: 36355361∟.
Observational study. ˍ
Hazaymeh
M, Löber-Handwerker R, Döring K, Abboud T, Mielke D,
Rohde V, Malinova V.
Prognostic
differences and implications on treatment strategies between
butterfly glioblastoma and glioblastoma with unilateral corpus
callosum infiltration.
Sci
Rep. 2022 Nov 10;12(1):19208∟.
doi: 10.1038/s41598-022-23794-6∟.
PMID: 36357498∟.
Observational
study. ˍ
Nagane M, Ichimura K, Onuki R,
Narushima D, Honda-Kitahara M, Satomi K, Tomiyama A, Arai Y,
Shibata T, Narita Y, Uzuka T, Nakamura H, Nakada M, Arakawa Y,
Ohnishi T, Mukasa A, Tanaka S, Wakabayashi T, Aoki T, Aoki S,
Shibui S, Matsutani M, Ishizawa K, Yokoo H, Suzuki H, Morita S,
Kato M, Nishikawa R.
Bevacizumab
beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK):
Phase II Safety, Efficacy and Biomarker Study.
Cancers
(Basel). 2022 Nov 10;14(22):5522∟.
doi: 10.3390/cancers14225522∟.
PMID: 36428615∟.
Interventional study. ˍ
Wang
J, Huang Y, Zhao F, Chen J, He L, Liu Z, Pei Y, Wei Z, Li R, Ai P,
Peng X.
Standard
or extended STUPP? Optimal duration of temozolomide for patients
with high-grade gliomas: a retrospective analysis.
J
Neurooncol. 2022 Nov 10∟.
doi: 10.1007/s11060-022-04162-w∟.
PMID: 36357822∟.
Observational study˰ ˍ
*
De Lucia F, Lefebvre Y, Lemort
MP.
Interest
of routine MR spectroscopic techniques for differential diagnosis
between radionecrosis and progression of brain tumor lesions.
Eur
J Radiol Open. 2022 Nov 11;9:100449∟.
doi: 10.1016/j.ejro.2022.100449∟.
PMID: 36386763∟.
Interventional study. ˍ
Saito
T, Mizumoto M, Liang HK, Nakai K, Sumiya T, Iizumi T, Kohzuki H,
Numajiri H, Makishima H, Tsurubuchi T, Matsuda M, Ishikawa E,
Sakurai H.
Factors
Involved in Preoperative Edema in High-Grade Gliomas.
Cureus.
2022 Nov 11;14(11):e31379∟.
doi: 10.7759/cureus.31379∟.
PMID: 36514578∟.
Observational study. ˍ
Nakagawa T, Kijima N, Hasegawa K,
Ikeda S, Yaga M, Wibowo T, Tachi T, Kuroda H, Hirayama R, Okita Y,
Kinoshita M, Kagawa N, Kanemura Y, Hosen N, Kishima
H.
Identification
of glioblastoma-specific antigens expressed in patient-derived
tumor cells as candidate targets for chimeric antigen receptor T
cell therapy.
Neurooncol
Adv. 2022 Nov 15, 2023;5(1):vdac177∟.
doi: 10.1093/noajnl/vdac177∟.
PMID: 36601313∟.
Laboratory investigation. ˍ
Plaha P, Camp S, Cook J,
McCulloch P, Voets N, Ma R, Taphoorn MJB, Dirven L, Grech-Sollars
M, Watts C, Bulbeck H, Jenkinson MD, Williams M, Lim A, Dixon L,
Price SJ, Ashkan K, Apostolopoulos V, Barber VS, Taylor A;
FUTURE-GB collaborators, Nandi D.
FUTURE-GB:
functional and ultrasound-guided resection of glioblastoma - a
two-stage randomised control trial.
BMJ
Open. 2022 Nov 15;12(11):e064823∟.
doi: 10.1136/bmjopen-2022-064823∟.
PMID: 36379652∟.
Interventional study. ˍ
Tao
Q, Zhu T, Ge X, Gong S, Guo J.
The
efficacy and safety of low-dose temozolomide maintenance therapy
in elderly patients with glioblastoma: a retrospective cohort
study.
Ann
Palliat Med. 2022 Nov [15];11(11):3513-3519∟.
doi: 10.21037/apm-22-1255∟.
PMID: 36464967∟.
Observational study. ˍ
Vázquez M, Bachmann N,
Pica A, Bolsi A, De Angelis C, Lomax AJ, Weber DC.
Early
outcome after craniospinal irradiation with pencil beam scanning
proton therapy for children, adolescents and young adults with
brain tumors.
Pediatr
Blood Cancer. 2022 Nov 15, 2022:e30087∟.
doi: 10.1002/pbc.30087∟.
PMID: 36377685∟.
Observational study. ˍ
Wang
Q, Lin W, Liu T, Hu J, Zhu Y.
Immunological
classification of glioblastoma and its prognostic implications.
Am
J Transl Res. 2022 Nov 15;14(11):8009-8022∟.
PMID: 36505340∟.
Laboratory investigation. ˍ